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a  b  s  t  r  a  c  t
Cutaneous  head  and neck  tumors  mainly  comprise  malignant  melanoma,  squamous  cell  carcinoma,
trichoblastic  carcinoma,  Merkel  cell  carcinoma,  adnexal  carcinoma,  dermatoﬁbrosarcoma  protuberans,erkel cell carcinoma
ermatoﬁbrosarcoma
asal cell carcinoma
clerodermiform carcinoma
ohs surgery
entinel node
sclerodermiform  basalioma  and  angiosarcoma.  Adapted  management  requires  an  experienced  team  with
good  knowledge  of  the  various  parameters  relating  to  health  status,  histology,  location  and  extension:
risk  factors  for aggression,  extension  assessment,  resection  margin  requirements,  indications  for  speciﬁc
procedures,  such  as  lateral  temporal  bone  resection,  orbital  exenteration,  resection  of  the  calvarium  and
meningeal  envelopes,  neck  dissection  and  muscle  resection.
©  2014 Published  by  Elsevier  Masson  SAS.
richoblastic carcinomaAbbreviations: AC, Adnexal carcinoma; AJCC, American Joint Committee on
ancer; BAD, British Association of Dermatology; BCC, Basal cell carcinoma;
T,  Computed tomography; DFSP, Dermatoﬁbrosarcoma protuberans; FDG, Fluo-
odeoxyglucose; GCS/GDS, German Cancer Society/German Dermatologic Society;
CC, Merkel cell carcinoma; MCPyV, Merkel-cell polyomavirus; MM,  Malignant
elanoma; MMS,  Mohs micrographic surgery; MRI, Magnetic resonance imaging;
TM,  Multidisciplinary team meeting; NCCN, National Comprehensive Cancer Net-
ork; NCI, National Cancer Institute; NHMRC, National Health and Medical Research
ouncil (Australia); PET, Positron emission tomography; SCC, Squamous cell car-
inoma; SFD, Société franc¸ aise de dermatologie (French Dermatology Society); SN,
entinel node; TNM, Tumor node metastasis; UICC, Union for international cancer
ontrol; WLE:, Wide local excision.
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879-7296/© 2014 Published by Elsevier Masson SAS.1. Aggression risk in malignant cutaneous tumors of the
face
The tumors referred to in this section are non-melanocytic
tumors at risk of deep extension or recurrent non-melanocytic
tumors: sclerodermiform basalioma, aggressive squamous cell car-
cinoma, trichoblastic carcinoma, adnexal carcinoma (microcystic
adnexal carcinoma and sweat-gland carcinoma), Merkel-cell carci-
noma and dermatoﬁbrosarcoma protuberans.
1.1. Topographic factors
Skin cancer tends to develop in photo-exposed regions; the head
and neck region is particularly at risk (75% of skin cancers). Certain
locations are at particular risk of aggressive tumor and recurrence:
• convex photo-exposed regions: cheek, temple;
376 M.  Durbec et al. / European Annals of Otorhinolaryngology, Head and Neck diseases 131 (2014) 375–383
Table 1
AJCC non-melanocytic cancer TNM classiﬁcation.
T: primary tumor
TX Insufﬁcient information for classiﬁcation of primary
T0 No sign of primary
Tis In-situ carcinoma
T1  Tumor ≤ 2 cm in longest dimension
T2  Tumor > 2 cm in longest dimension
T3  Tumor extending to deep structures such as muscle,
bone, cartilage, jaw or orbit
T4 Tumor with direct or perineural invasion of skull base
or  axial skeleton
In  synchronous multiple tumor, the tumor with the highest T category is
counted, with the number of tumors found shown in brackets
N:  regional adenopathies
NX Insufﬁcient information for classiﬁcation of regional
lymph-node involvement
N0 No sign of regional lymph nodes
N1 Involvement of 1regional lymph node, ≤ 3 cm in
longest dimension
N2 Involvement of 1regional lymph node, > 3 cm
and ≤ 6 cm in longest dimension or multiple
involvement but none > 6 cm
N3 Involvement of regional lymph-node > 6 cm in longest
dimension
M:  remote metastasis
M0 No remote metastases
M1  Remote metastasis/es
Table 2
Non-melanocytic TNM cancer staging.
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3
T1, T2, T3
N0
N1
M0
M0
Stage IV T1, T2, T3 N2, N3 M0
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Table 3
Histologic factors of poor prognosis in primary skin tumor.
Cutaneous squamous cell
carcinoma
Breslow’s depth > 2 mm or Clark
level ≥ 4
Perineural invasion
Weak differentiation
Basal cell carcinoma Histologic type: sclerodermiform,
inﬁltrating or metatypic
(basosquamous)
Perineural invasion
Melanoma Breslow’s depth
Ulceration
Mitosis count ≥ 1/mm2
Clark level
Vascular, lymphatic and perineural
invasion
Merkel cell carcinoma Diffuse architecture
Breslow’s depth
2.1.3. Meningeal extension
MRI  is the examination of choice for cranial extension.
Meningeal invasion is to be suspected in case of thickening and
Table 4
Extension assessment guidelines and radiologic follow-up per type of skin tumor.
Basal cell
carcinoma
No systematic extension assessment
In case of deep or locoregional invasion
lymph-node extension: cervical ultrasound or CT
local soft tissue, perineural or intracerebral extension: MRI
bone extension: bone scan
Squamous cell
carcinoma
In-situ carcinoma and patients without prognostic risk
factors: cervical lymph-node ultrasonography
In  case of prognostic risk factors and/or clinical alarming
signs: cervicothoracic CT, abdominal-pelvic CT, cerebral CT
In  case of risk factors for perineural extension and/or
neurologic clinical signs: MRI  of intra- and extra-cerebral
trajectory of cranial pairs
Surveillance: cervical and parotid lymph-node
ultrasonography every 6 months for 5 years
Melanoma Stage II (AJCC): cervical lymph-node ultrasonography
Stage III: cervicothoracic, abdominal-pelvic and cerebral
CT  (full body)
Small cell
Merkel’s
carcinoma
Locoregional and cervical lymph-node
ultrasonography + full-body CT (thoracic-abdominal-pelvic
and cervico-encephalic)T4
All T
All N
All N
M0
M1
peri-oriﬁce regions, as these derive from fusion of embryonic
buds on the median line, with low tissue resistance, allowing deep
inﬁltration, especially along nerve axes.
In melanoma, location has relatively little impact on prognosis
ompared to the major factors of thickness (Breslow’s depth) and
etastatic involvement (see 1.3, “Histologic factors of poor prog-
osis”, below). Even so, facial locations are considered as being at
ntermediate risk, and scalp and neck locations at high risk (level
f evidence 2) [1].
.2. Tumor size
In the 7th edition of the AJCC’s TNM classiﬁcation of non-
elanocytic tumor, tumor size no longer counts except to
istinguish between stages T1 (≤ 2 cm)  and T2 (> 2 cm), [2,3]
Tables 1 and 2).
.3. Histologic factors of poor prognosis in primary skin tumor
Other than size, histologic prognostic factors play a major role in
umoral aggressiveness and recurrence risk [2,3] (level of evidence
) (Table 3)..4. Immunosuppression
Skin cancer in immunosuppressed patients often shows evolu-
ion requiring rapid treatment.Mitoses
Vascular or lymphatic emboli
2. Extension assessment by imaging
2.1. Local and contiguous extension assessment
2.1.1. Soft tissue extension
MRI  is the key examination for detection, local assessment and
monitoring of evolution, due to its excellent diagnostic sensitivity
in soft tissue (Table 4).
It enables objective assessment of depth extension, to determine
the possibilities of resection, and reproducible target measure-
ments for follow-up under radiochemotherapy.
2.1.2. Bone extension
In case of suspected underlying bone extension, CT with bone
reconstruction is recommended. Bone involvement is to be strongly
suspected in case of cortical lysis and/or permeation, periosteal
reaction or osteocondensation in contact with the lesion. Cancel-
lous bone invasion, however, is better assessed on MRI.In case of MTM  decision: head and neck MRI, brain MRI,
PET scan
Surveillance assessment: locoregional and cervical
lymph-node ultrasonography every 3 months for 2 years,
then every 6 months; full-body CT according to initial
involvement, especially in case of lymph-node metastasis
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ontrast uptake in the meningeal envelopes adjacent to the tumoral
ysis of the skull.
Guideline 1
In facial tumor with deep extension, head and neck CT and
MRI  should be associated for exhaustive exploration of the
various tissular structures (Expert opinion).
Pre-treatment imaging assessment is essential to manage-
ment and requires good anatomic knowledge and skill in head
and neck imaging, as well as coordination with the clinician
(Expert opinion).
.2. Remote extension assessment
.2.1. Lymph-node extension
Classical examination is indispensable but shows limited sensi-
ivity (Table 4).
Ultrasonography shows better sensitivity and speciﬁcity than
imple clinical examination [4] (level of evidence 1). It is also non-
nvasive, inexpensive and easily reproducible although operator-
ependent.
CT provides lymph-node visualization, while being easier for the
linician to interpret and less operator-dependent. It is the refer-
nce examination due to its high deﬁnition. It has the drawback of
eing irradiating, and should not be unnecessarily repeated.
MRI  also shows good deﬁnition and easily interpreted images.
t is not irradiating, but has well-known material contraindications
clips and metal implants, pacemaker, etc.) and is poorly tolerated
y claustrophobic patients.
18FDG PET-CT is effective in screening for remote metastasis,
ut does not seem preferable to the previous three examina-
ions for diagnosis of locoregional lymph-node metastasis [4] (level
f evidence 2). The technique is improving, but does not eas-
ly detect < 10-mm adenopathies, with a 2–6% false-positive rate,
epending on the series, in both lymph nodes and tissue, due to
ocal scarring, inﬂammation or infection [5] (level of evidence 4).
Ultrasound- or CT-guided ﬁne-needle aspiration is only con-
ributive when positive; negative ﬁndings do not allow extension
 status to be determined.
The sentinel node (SN) technique, described by Morton in 1990
6,7], uses 99mTc, a radiotracer injected around the lesion. Lym-
hatic drainage basins are located by skin marking by a gamma
robe, 2 hours after injection [8] (level of evidence 4). Limited
amma-probe guided skin incisions centered on the skin markings
dentify the adenopathies serving as initial relay. Any lymph-node
pecimens are sent for pathologic analysis. Frozen section biopsy
s useful in SCC, as it allows dissection in the same step, but is of
o interest in malignant melanoma (MM).  Difﬁculty in identifying
he SN in case of head and neck skin tumor may  be due to mask-
ng “background noise” if the tumor site is close to the SN, to the
urgeon’s learning curve, to excessive tracer injection or excessive
nterval between injection and surgical location. According to some
uthors, parotid location is a contraindication to sampling (greater
isk of facial nerve lesion than in surgical parotidectomy) [8,9] (level
f evidence 4). The new portable gamma-cameras seem to enhance
recision [10] (level of evidence 2).So-called “functional” selective dissection is more reliable, but
ore invasive, with risk of neural complications (notably VII and
I), scarring and functional impairment, and is therefore indicated
f and only if prognosis is sufﬁciently improved by ﬁrst-line dis-
ection in case of N0 or complementary dissection in case of SN
ositivity.gy, Head and Neck diseases 131 (2014) 375–383 377
2.2.2. Remote visceral extension
Chest X-ray and abdominal ultrasonography can usefully be
replaced by thoracic-abdominal-pelvic CT to screen for lung and
liver metastasis, completed by brain scan. Thoracic CT screens for
mediastinal adenopathies, pulmonary parenchymatous locations
and less frequent pleural and osseous locations.
Abdominal-pelvic CT screens for secondary liver and bone loca-
tions.
Contrast-enhanced cerebral CT screens for cerebral-meningeal
metastasis.
Assessment may be completed by PET scan (see below, 2.3.2:
imaging in melanoma) or SN biopsy.
2.2.3. Perineural extension
Extension should be explored both in the skull-base foramina
and perineurally right along the nerve, from the initial lesion up
to the intracerebral nucleus; the nerve may  be discontinuous, and
therefore, the entire trajectory of the cranial nerves should be ana-
lyzed.
The nerves most frequently involved are, in descending order:
V2, V3, VII [11] (level of evidence 4) and, less frequently, V1 and the
vidian nerve.
It is recommended to explore systematically for perineural
lesion in case of proven deep extension or risk factors for aggres-
sion: lesion of the mid-face or of embryonic fusion areas, recurrent
skin tumor, histologically high-grade tumor, and high-growth
tumor with elevated risk of perineural inﬁltration [11] (level of
evidence 1).
The reference examination for perineural extension is MRI
[11–13] (level of evidence 4). Perineural inﬁltration usually shows
as hypersignal on T2-weighted sequences and uptake in the nerve,
which is of increased size. The skull-base foramen involved is usu-
ally enlarged. Signal abnormality may  extend to the cavernous
sinus, trigeminal cave and cerebral parenchyma.
Guidelines for remote extension assessment according to tumor
type are presented in sub-section 2.3 (below).
2.3. Remote extension according to tumor type: squamous cell
carcinoma, malignant melanoma and Merkel cell carcinoma
While basal cell carcinoma does not require extension assess-
ment, other skin tumors do. We  detail below the indications for
remote extension assessment in inﬁltrating SCC, MM and MCC.
2.3.1. Inﬁltrating SCC
Facial SCC involves a high risk of lymph-node metastasis
(0.3–16%, according to series) [14,15] (level of evidence 4).
Risk of lymph-node metastasis is increased by the following
prognostic factors [16,17] (expert opinion):
• clinical parameters:
◦ size > 2 cm,
◦ location (lip, ear, nose, non-photo-exposed areas, etc.),
◦ poorly visible margins,
◦  immunosuppression (major risk factor),
◦ local recurrence of SCC,
◦ rapid growth tumor,
◦  neurologic symptoms of invasion,
◦ tumor on scar tissue (burn or trauma), previous radiation ther-
apy, ulcerated tumor site;
• histopathologic parameters:◦ thickness >4 mm and depth (Clark levels IV or V), indicating
deep adherence and risk of extension: Clark V lesions > 5 or 6 cm
show > 15% remote extension risk [17] (level of evidence 3);
◦ moderate or low cellular differentiation;
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◦ form: acantholytic SCC, mucoepidermoid SCC, desmoplastic
SCC;
◦ perineural invasion (2–14% depending on series).
The perineural extension risk factors in SCC are:
mid-face location;
embryonic fusion area;
recurrent skin tumor;
high histologic grade;
high growth rate.
In SCC with low risk of evolution, as in in situ SCC, no comple-
entary examinations are required. In high-risk SCC, locoregional
ymph-node areas should be examined on ultrasound. Other exam-
nations are to be discussed in the multidisciplinary team meeting
MTM). Some teams use CT and MRI. The precision of PET-CT is
mproved by coupling to ultrasonography or MRI. SN biopsy should
e used only in experienced centers [18] (level of evidence 4).
egarding neck dissection:
for patients assessed as N0, neck dissection may  be decided on in
the MTM  in case of major risk factors;
it may  be decided on in the MTM  in case of positive SN biopsy;
it is indispensable in N+ patients.
Impact on survival does not differ between radical and func-
ional neck dissection [10,19] (level of evidence 1).
Guideline 2 (Expert opinion)
SCCs with low risk of evolution and in-situ tumors do not
require complementary examination, whereas tumors with
deep extension or high risk of evolution require cervical ultra-
sonography (lymph-node assessment). Other examinations
(CT, PET-CT and SN) are indicated only on MTM  decision. When
indicated, SN biopsy should be performed by an experienced
team.
NB: Radiologic follow-up.
Although somewhat outside the scope of this article, it should
e noted that radiologic follow-up of facial SCC consists of simple
linical surveillance in case of low risk of evolution and locoregional
ltrasound scan of the lymph-node drainage basin every 6 months
or 5 years in case of risk of aggression [17] (expert opinion). Other
ssessments are made on MTM  decision according to risk level or
ntercurrent clinical events.
.3.2. Malignant melanoma
There is a 15% to 20% rate of occult lymph-node metastasis in
0 patients with head and neck melanoma [20] (expert opinion).
t is therefore essential for locoregional extension assessment to
xplore for infraclinical adenopathies if lymph-node area palpation
ppears normal. The most frequent form of evolution (70% of cases
f extension) in melanoma is locoregional spread (in-transit and
ocoregional lymph-node metastases) and assessment should be
erformed according to AJCC/UICC stage [11] (level of evidence 2).
ystematic SN biopsy is not recommended in clinically N0 patients
expert opinion). The procedure may, however, be performed in
M with > 1-mm thickness or ulceration, positive ﬁndings having
rognostic value [21] (level of evidence 4), or even, according to cer-
ain authors, in thinner MM [22] (level of evidence 4), sometimes
ssociated to ultrasound to improve precision [23]. Slides should be
ead on immunohistochemistry (S100, HMB45, etc.). Prophylactic
unctional neck dissection in N0 patients appears to have no impactgy, Head and Neck diseases 131 (2014) 375–383
on overall survival (equal survival with prophylactic, secondary or
no dissection) [24] (expert opinion). Neck dissection in case of pos-
itive SN reveals further lymph-node metastases in 16–28% of cases
depending on the study [25] (level of evidence 3), but does not
affect overall survival or metastatic evolution.
Guideline 3
In AJCC stage I N0 melanoma and in situ melanoma, no
complementary examinations are necessary (expert opinion).
In stage IIa and b N0 melanoma, lymph-node drainage area
ultrasonography should be performed (expert opinion).
In stage IIc and III, ultrasonography should be completed by
complementary imaging (CT, MRI  or PET-CT) on MTM  decision
(expert opinion). SN biopsy is an option in clinically N0 patients
depending on Breslow’s depth and possible ulceration (expert
opinion).
N stages other than 0 and positive SN biopsy require imag-
ing on MTM  decision.
NB: Radiologic follow-up.
Although somewhat outside the scope of this article, it should
be noted that radiologic follow-up in MM comprises:
• no systematic paraclinical work-up in AJCC stage I (grade II);
• in stage II and III, as well as complete clinical examination every
3 months for 5 years, lymph-node drainage area ultrasonography
every 3 to 6 months is justiﬁable without being indispensable
(expert opinion). The need for and rhythm of surveillance imaging
should be decided in the MTM.
2.3.3. Merkel cell carcinoma
MCC  is rare but aggressive, to be differentiated from neu-
roendocrine or small-cell skin cancer. Abnormal DNA repair is
implicated in MCC  [26], generally affecting patients over 50 years
of age. Lymph-node invasion is considerable (50–80% depending
on the series) (level of evidence 4). Fifty percent of patients receiv-
ing prophylactic neck dissection show micrometastasis according
to Goepfert et al. [27] (level of evidence 4). Most authors therefore
recommend complementary examination (CT, MRI and PET) as of
initial assessment [28,29].
Guideline 4 (Expert opinion)
In Merkel cell carcinoma, cervical ultrasonography should
be systematic, as should thoracic-abdominal-pelvic and head-
and-neck CT, given the frequency of metastasis. MRI and PET-
CT are to be discussed in MTM, as is SN.
In clinically N0 patients, surgical revision to enlarge resection
after histologic diagnosis may  be completed by SN biopsy with
extemporaneous examination, or primary prophylactic neck dis-
section according to MTM  decision. In non N-0 stages, neck
dissection is mandatory, and classical 3-monthly clinical and ultra-
sound follow-up should include imaging as at initial assessment.
NB: Radiologic follow-up.
Although somewhat outside the scope of this article, it should
be noted that radiologic follow-up in MCC  comprises:• iterative clinical examination every 3 months for 2 years, then
every 6 months;
• locoregional ultrasonography and full-body CT or PET-CT at a
rhythm decided on in MTM.
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Table  5
Indications and interest of imaging examinations according to tumor location.
Topography Examination Speciﬁc analyses
Periorbital region MRI  Eyelids
Orbit contents: extra- and
intra-conic fat, muscles,
eyeball, optic nerve, nerve V2
Tear ducts
CT Orbit edge
Papyraceous plate
Orbital ﬂoor/roof
Maxillary/ethmoid sinus bone
walls
Skull base with neural foramen
Auricular region CT Tympanic bone, mastoid,
petrous pyramid
arcade
MRI  Pinna
Nerve VII
Meningeal/brain tissue
Nose, lips, cheek,
parotid region
MRI  Cutaneous, fatty, muscular,
cartilage and neural (V2, V3,
VII) structures, parotid gland
CT Superior maxillary, zygoma,
zygomatic arcade, mandibular
bone, sinus walls, skull base
with neural foramen
Scalp and forehead CT External/internal cortical bone,
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MRI  Intracranial meningeal and
cerebral extension, nerve V1
.4. Remote extension assessment according to tumoral
opography
Table 5 presents indications for imaging according to tumoral
opography.
. Deﬁnition of safe margins in cutaneous resection
This section excludes the question of resection margins in
elanoma with deep extension, considered as a general disease.
Malignant tumors are resected with lateral and deep safety mar-
ins, as they frequently show microscopic extension, leading to
ocal recurrence. Resection should be guided by histologic diagnosis
nd by tumor subtype and depth of invasion as determined by prior
iopsy. Prior biopsy is not mandatory for clinically typical nodular
asal cell carcinoma (BCC) and is contraindicated in suspicion of
elanoma. The reliability of the histologic study of the margins
an be enhanced if the surgeon indicates which areas are most
linically suspect. Extemporaneous examination is an alternative,
sing frozen sections to provide information and guiding any intra-
perative revision, but cannot be used in certain complex histologic
iagnoses [30–32] (level of evidence 4). The reference technique is
ohs micrographic surgery (MMS), in which iterative sectioning is
uided by intra-operative margin analysis on frozen sections, with
omplete visualization of lateral and deep margins, after an ini-
ial resection restricted to the macroscopic tumor [33–34] (level
f evidence 1) [35] (level of evidence 4). This technique improves
ure rates, maximizing sparing of healthy tissue, which is especially
nteresting where the face is concerned. It is, however, available in
nly a few centers in France, making it poorly adapted to the high
ate of skin tumor and the reality of the French health care sys-
em. “Slow-Mohs” is a variant in which margins are checked as in
MS  but with analysis on parafﬁn-conserved sections performed
ome days later, requiring iterative surgical revision and covering
36] (level of evidence 4). In centers that do not perform MMS  or
low-Mohs, two-step resection is possible, based on classic (i.e.,
artial) histopathologic margin analysis. Any revision and defect
overing is postponed for a few days, depending on the pathologygy, Head and Neck diseases 131 (2014) 375–383 379
results. Compared to the standard procedure, two-step resection
thus avoids sacriﬁce of ﬂaps in case of initially incomplete resection.
Guideline 5
The Mohs technique should be used where practically fea-
sible (expert opinion).
3.1. Guidelines for margins in sclerodermiform basalioma [36–44]
Guideline 6
Ten-millimeter lateral margins should be respected in
sclerodermiform basalioma, whether recurrent or not, to be
adapted according to location and extended in case of large
tumor (Recommendation grade A). Deep margins should
extend to the hypodermis and reach, while respecting (unless
invaded), the aponeurosis (forehead), perichondrium (ear,
nose) and periosteum (scalp) (Recommendation grade C).
No complex closure should be performed before obtain-
ing intra- or postoperative assessment of resection quality
(Recommendation grade C). MMS  should be considered in
sclerodermiform basalioma of facial area H (Recommendation
grade C), facial BCC exceeding 2 cm (Recommendation grade
A) and recurrence (Recommendation grade A), while allowing
for the difﬁculty of access to MMS  in France.
3.2. Squamous cell carcinoma (SCC) [45,46,36,47,37]
Guidelines for MMS  in SCC reﬂect the differences in access to
the technique in different countries [48–52] (level of evidence 1).
Guidelines on MMS  indications vary widely between different sci-
entiﬁc societies: BAD, NCCN, NHMRC, NCI, GSC/GDS [49–52].
Guideline 7
Four-millimeter lateral margins should be respected (Rec-
ommendation grade A) in low-risk SCC and at least 6-mm
margins in high-risk SCC (i.e., with at least 1 recurrence risk
factor: see section 2.1.3.1, above) (Recommendation grade A).
Margins should be increased to 10 mm or even more in case
of cumulative risk factors for infraclinical extension: incom-
plete primary resection, high histologic grade, Clark level V,
perineural invasion (Recommendation grade C).
Deep margins should be proportional to lateral margins,
preferably reaching the periosteum in the forehead and scalp
and the muscular aponeurosis in the neck. Resection should
usually cross nose and ear cartilage (expert opinion).
It is often difﬁcult to respect intended margins without
impairing functional prognosis. Such cases require highly spe-
cialized management (Recommendation grade C).
3.3. Adnexal carcinoma (AC)
There are at present no published scientiﬁc guidelines for sur-
gical treatment of AC. It is not unusual for diagnosis to be founded
on deﬁnitive histology of the surgical specimen, which reduces the
possibilities of earlier guidance of resection. AC is usually classiﬁed
as eccrine sweat-gland carcinoma, apocrine sweat-gland carci-
noma, sebaceous carcinoma or pilar carcinoma [53,54] (level of
evidence 4). For the purposes of the present treatment guidelines,
AC is classiﬁed by 3 levels of aggressiveness: low malignancy with
3 yngology, Head and Neck diseases 131 (2014) 375–383
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Guideline 10 [58,59]
Regarding adjuvant treatment in MCC, it is recommended
to associate radiation therapy to surgery, as it provides ben-
eﬁt in terms of locoregional recurrence and overall survival
(Recommendation grade B). Chemotherapy has been tried in
remote metastasis, but at present, no prognostic beneﬁt has80 M.  Durbec et al. / European Annals of Otorhinolar
are recurrence; mainly local malignancy with frequent infraclin-
cal extension and perineural invasion; and systemic malignancy
ith high risk of local recurrence, regional and visceral metastasis
nd death.
Guideline 8
Five-millimeter lateral margins should be respected in
low-malignancy AC (superﬁcial eccrine porocarcinoma and
trichilemmal carcinoma) (Recommendation grade C); 10 mm
in mainly locally malignant AC other than microcystic adnexal
carcinoma (trichoblastic carcinoma, eccrine mucinous carci-
noma, malignant pilomatricoma, cystic adenoid carcinoma
and eccrine syringomatous carcinoma) (Recommendation
grade C); 10 to 20 mm in systemically malignant AC (apocrine
sweat-gland carcinoma, inﬁltrating eccrine porocarcinoma,
ocular and extra-ocular sebaceous carcinoma, spiradenocarci-
noma and hidradenocarcinoma) (Recommendation grade C);
and ≥ 20 mm in microcystic adnexal carcinoma (Recommenda-
tion grade C). Deep margins should extend to the hypodermis
and reach, while respecting (unless invaded), the aponeurosis
(forehead), perichondrium (ear, nose) and periosteum (scalp)
(Recommendation grade C). MMS  should be used in ﬁrst
intention in microcystic adnexal carcinoma (Recommendation
grade B) and considered in inﬁltrating eccrine porocarcinoma,
ocular sebaceous carcinoma (Recommendation grade C) and
in difﬁcult, notably peri-oriﬁce, locations (Recommendation
grade C), while allowing for the difﬁculty of access to MMS
in France.
.4. Merkel cell carcinoma (MCC)
MCC  is a rare primary neuroendocrine skin tumor, aggressive,
ith high risk of recurrence and locoregional and remote metasta-
is. Treatment associates surgical resection, radiation therapy and
hemotherapy, but is poorly codiﬁed due to the rarity of the condi-
ion and lack of randomized prospective comparative studies [55]
level of evidence 4) [56,57] (level of evidence 3).
Guideline 9
Most cases of MCC  are treated by wide local excision (WLE)
of the primary and the drainage lymph nodes.
Regardless of tumor size, if there is no regional or remote
metastasis, resection of primary MCC  should be total, with
histologic margin analysis.
In the face, where WLE  is difﬁcult, a 1-cm lateral margin may
be enough if validated in MTM  (Recommendation grade B) or
Mohs micrographic examination may  be used.
Reconstruction can usually be associated in the same step,
or later in case of extensive tumor, ensuring safe margins and
preferably using simple techniques so as to facilitate surgical
site surveillance (Recommendation grade B).
SN biopsy-resection should be performed in the same step
as resection of primary MCC  (Recommendation grade B). If
SN examination ﬁnds tumoral invasion, complementary neck
dissection is indicated, even though it is uncertain whether this
improves overall survival (Recommendation grade C).
.5. Dermatoﬁbrosarcoma protuberans (DFSP)DFSP is a rare ﬁbroblastic skin tumor which is nevertheless the
east exceptional skin sarcoma. The clinical aspect is of a large
mbossed multinodular tumor adhering to the surface of the skinbeen demonstrated (Recommendation grade B).
and inﬁltrating the dermis and hypodermis often beyond palpable
limits.
Overall annual incidence is estimated at 1–4 per million and sex
ratio is close to 1. Diagnosis is usually in the 3rd or 4th decade of
life, although all ages may  be affected [60] (level of evidence 4).
DFSP is an essentially local sarcoma of low-to-intermediate
malignancy. Remote metastasis is rare.
MMS considerably reduces the risk of incomplete resection and
unnecessary sacriﬁce of healthy tissue.
There are few speciﬁc studies of head and neck DFSP treatment.
Guideline 11
The choice of surgical technique for DFSP should take
account tumor size and location and the blemish resulting
from surgery. In head and neck locations, Mohs micrographic
surgery (MMS) is recommended in ﬁrst intention, due to the
difﬁculty of wide local excision (WLE) in this region (Recom-
mendation grade B). MMS  should be performed by a team with
dedicated experience, as it is difﬁcult. If MMS  is not available,
WLE  with 2–4-cm lateral margins is recommended, ablating
the aponeurosis in depth. All margins should be examined on
histology before ﬁnal reconstruction. If there is any doubt as
to the completeness of resection, total skin graft rather than
ﬂaps should, if possible, be used, to enable detection of deep
recurrence (Recommendation grade B).
3.6. Angiosarcoma
Cutaneous angiosarcoma is rare, mainly encountered in elderly
subjects in the head and neck region; it accounts for 4–5% of skin
sarcomas [61] (level of evidence 2). It is locally highly aggressive
and also gives rise to metastasis, mainly in lung and liver [62] (level
of evidence 3). This explains the poor prognosis, with 25–50% over-
all 5-year survival, depending on the series [63] (level of evidence
3).
Guideline 12
In angiosarcoma, the widest possible resection (2–5 cm
margins) should be performed, while allowing acceptable
quality of life (Recommendation grade C).
4. Resection principles according to topography: practical
questions
4.1. When to perform parotidectomy? [64–69]The parotid is the main site of lymph-node metastasis in facial
carcinoma (SCC, AC) and melanoma. Its lymphatic network is rich,
draining the temporal region and cheek.
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Guideline 13
In immunocompetent patients with temporal or auricular
skin tumor exceeding 2 cm in size or showing deep inﬁltra-
tion (thickness > 4–5 mm)  and in immunosuppressed patients,
parotid MRI  should screen for infraclinical metastasis (Recom-
mendation grade B). In clinically and radiologically N0 patients,
SN biopsy is an option (Recommendation grade C).
Prophylactic parotidectomy is not recommended in
immunocompetent patients without clinical metastasis (Rec-
ommendation grade B).
The parotid regional should be monitored clinically every
2 months in non-immunocompetent patients or in case of unfa-
vorable anatomopathologic factors (Recommendation grade
B).
When parotid metastasis is detected, conservative facial
nerve parotidectomy should be performed and completed by
targeted lymphadenectomy in clinically N0 patients, followed
by radiation therapy to the parotid area, but without irradiating
the neck if lymphadenectomy is negative (Recommendation
grade B).
In case of clinically inﬁltrating carcinoma adjacent to the
parotid, en bloc parotidectomy should be associated to skin
4
4
In locally advanced carcinoma inoperable due to local
extension or general health status precluding heavy surgery,
medical management should be proposed in a palliative per-
spective (Recommendation grade A).
In palliative contexts, fractionated radiation therapy may  be
proposed as analgesic (Recommendation grade B).
Targeted therapy, such as Hedgehog pathway inhibitors in
locally advanced BCC (GDC-0449: Vismodegib) is not to be
considered outside of clinical trials (Recommendation grade
B).
4.5. Principles of lymph-node resection in cutaneous facial tumor
[79–83]
Guideline 17
In lymphophilic tumor, exhaustive lymph-node stagingresection.
.2. When to perform lateral temporal bone resection? [70]
Guideline 14
Extension assessment should be performed in case of
tumor in the external auditory canal or adjacent areas, to
determine indications for and type of lateral temporal bone
resection (Recommendation grade C).
.3. When to perform orbital exenteration? [71–76]
Guideline 15
In tumors strictly limited to the eyelid, without scleral inva-
sion, resection may  be performed, respecting established safe
margins. One or both eyelids should be repaired so as to guar-
antee protection of the eyeball (Recommendation grade C).
In case of superﬁcial extension to the tunica conjunctiva
bulbi of the sclera (tumor remote from the sclero-corneal junc-
tion, with mobile sclera connective layer over a ﬁbrous layer),
resection without exenteration may  be performed (Recom-
mendation grade C).
In case of painful loss of vision, exenteration is formally
indicated if the procedure respects safe margins (Recommen-
dation grade C).
In case of invasion of the ﬁbrous layer of the sclera or
oculomotor or acuity disorder, the eyeball cannot usually be
spared. Evisceration (resection of eyeball content by decortica-
tion without resection of the sclera) and enucleation (resection
limited to the eyeball, sparing the adnexa) are not generally
indicated. Exenteration is the most logical attitude to guarantee
safe margins (Recommendation grade C).
Postoperative adjuvant radiation therapy is recommended
after wide resection involving exenteration (Recommendation
grade C).
Rehabilitation after exenteration preferably consists of
implanting a craniofacial prosthesis (Recommendation grade
C). Filling by a thick ﬂap should be avoided, as hindering pros-
thetic rehabilitation (Recommendation grade C).4.4. When to perform skull or meningeal resection? [77,78]
Guideline 16
In tumors that are perfectly mobile with respect to the
deep bone, resection is performed above the periosteal
plane, respecting established safety margins (Recommenda-
tion grade B).
If mobility is reduced or periosteal inﬁltration or external
cortical erosion is found intra-operatively, bone rasping may
be performed down to the diploe (expert opinion). Pathologic
bone analysis of deep margins is made impossible by the cho-
sen bone resection technique (expert opinion).
In case of bone invasion conﬁrmed on CT, skull resection
should be performed by a double team with a neurosurgeon.
Meningeal adherences to the internal side of the skull gener-
ally require meningeal plasty repair (autologous or synthetic)
associated to the same step. Superﬁcial tegument cover may
use a local rotation ﬂap associated to a skin ﬂap to the donor
site, or micro-anastomosed free ﬂap (Recommendation grade
C).
Radiation therapy is recommended as postoperative adju-
vant in case of bone invasion conﬁrmed on histology
(Recommendation grade A).
In locally advanced carcinoma inoperable due to local
extension or general health status precluding heavy surgery,
medical management should be proposed in a palliative per-
spective (Recommendation grade A).
In palliative contexts, fractionated radiation therapy may  be
proposed as analgesic (Recommendation grade B).
Targeted therapy, such as Hedgehog pathway inhibitors in
locally advanced BCC (GDC-0449: Vismodegib) is not to be
considered outside of clinical trials (Recommendation grade
B).should be performed (Expert opinion).
Lymph-node treatment should be given to all clinically,
radiologically or histologically N0 patients (Expert opinion).
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.6. When to perform muscle resection?
Guideline 18 (Expert opinion)
In the face, muscle resection always follows carcinologic
criteria for safe margins, with maximal sparing of structures.
Progress in surgical techniques allows more extensive
resection, improving local control, while providing acceptable
esthetic and functional results.
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